Acute Myelogenous Leukemia Clinical Trials

7 recruiting

Acute Myelogenous Leukemia Trials at a Glance

19 actively recruiting trials for acute myelogenous leukemia are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in New York, Cleveland, and New Haven. Lead sponsors running acute myelogenous leukemia studies include Institute of Hematology & Blood Diseases Hospital, China, Children's Hospital Medical Center, Cincinnati, and Center for International Blood and Marrow Transplant Research.

Browse acute myelogenous leukemia trials by phase

Treatments under study

About Acute Myelogenous Leukemia Clinical Trials

Looking for clinical trials for Acute Myelogenous Leukemia? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Acute Myelogenous Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Acute Myelogenous Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myelogenous Leukemia+7 more
Wake Forest University Health Sciences2,000 enrolled1 locationNCT01890486
Recruiting
Phase 1

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.266 enrolled18 locationsNCT06656494
Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hematologic MalignanciesInherited Disorders of MetabolismInherited Abnormalities of Platelets+2 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 2

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

Acute Myelogenous LeukemiaMyelodysplastic SyndromesAcute Lymphocytic Leukemia+1 more
Case Comprehensive Cancer Center36 enrolled1 locationNCT06904482
Recruiting

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Breast CancerOvarian CancerLung Cancer+2 more
Carevive Systems, Inc.25 enrolled7 locationsNCT05974150
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

LymphomaAMLLeukemia+7 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 1

A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

AMLMDSLeukemia+2 more
Cullgen (Shanghai),Inc45 enrolled3 locationsNCT07347171
Recruiting
Phase 3

The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia

AML (Acute Myelogenous Leukemia)Down Syndrome (DS)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology100 enrolled1 locationNCT07232134
Recruiting
Phase 2

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Fanconi AnemiaSevere Marrow FailureMyelodysplastic Syndrome (MDS)+1 more
Children's Hospital Medical Center, Cincinnati70 enrolled3 locationsNCT02143830
Recruiting
Phase 2

Cord Blood Transplant in Adults With Blood Cancers

Acute Myelogenous Leukemia (AML)
Memorial Sloan Kettering Cancer Center54 enrolled1 locationNCT05884333
Recruiting
Early Phase 1

The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

AMLAML (Acute Myelogenous Leukemia)
Institute of Hematology & Blood Diseases Hospital, China10 enrolled1 locationNCT07126782
Recruiting
Phase 2

Allo HSCT Using RIC and PTCy for Hematological Diseases

Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+15 more
Masonic Cancer Center, University of Minnesota56 enrolled1 locationNCT05805605
Recruiting
Phase 2

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Hodgkin LymphomaLymphomaAcute Myelogenous Leukemia+5 more
Leland Metheny20 enrolled1 locationNCT06680661
Recruiting
Phase 1Phase 2

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

AML (Acute Myelogenous Leukemia)Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting

Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade

AML (Acute Myelogenous Leukemia)
IRCCS Azienda Ospedaliero-Universitaria di Bologna20 enrolled1 locationNCT06874257
Recruiting
Phase 1

CD123-CD16-NK Cells Immunotherapy for AML

AML (Acute Myelogenous Leukemia)NK CellCD123+ Acute Myeloid Leukemia
Chunji Gao9 enrolled1 locationNCT06835140
Recruiting
Phase 2

Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

AML (Acute Myelogenous Leukemia)
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06783790
Recruiting
Phase 2

Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML

AML (Acute Myelogenous Leukemia)
Institute of Hematology & Blood Diseases Hospital, China1,200 enrolled1 locationNCT06635681